Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL909282 | 0.77 | ALDH1A1 (0.53) | SLC1A3ALDH1A1PTGS2KDM4EKMT2A | |
| SCHEMBL23651542 | 0.77 | PTGS2 (0.34) | SLC1A3PTGS2 | |
| SCHEMBL25414764 | 0.72 | PTGS2 (0.33) | SLC1A3PTGS2 | |
| SCHEMBL1155426 | 0.70 | MAPK1 (0.40) | ALDH1A1PTGS2KDM4EKMT2AHSD11B1 | |
| SCHEMBL5998376 | 0.67 | ALDH1A1 (0.39) | ALDH1A1KDM4EKMT2A | |
| SCHEMBL3740763 | 0.66 | PTGS2 (0.59) | SLC1A3ALDH1A1PTGS2KDM4EHSD11B1 | |
| SCHEMBL19268185 | 0.66 | PTGS2 (0.37) | SLC1A3PTGS2HSD11B1 | |
| SCHEMBL2646281 | 0.65 | — | — | |
| SCHEMBL19272671 | 0.64 | PTGS2 (0.39) | SLC1A3PTGS2HSD11B1 | |
| SCHEMBL11983456 | 0.63 | ALDH1A1 (0.37) | ALDH1A1PTGS2KDM4EHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060270706-A1 | Cyclic amine derivative having heteroaryl ring | SANKYO COMPANY, LTD. (JP) | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270706-A1 | Cyclic amine derivative having heteroaryl ring | F12, F2, H1-3 | SLC1A3 1593/4885ALDH1A1 1073/4885PTGS2 2325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.